4QK Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.65 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.38 |
| Beta | 2.03 |
| 1 Month Change | -15.54% |
| 3 Month Change | 10.00% |
| 1 Year Change | -25.92% |
| 3 Year Change | -86.87% |
| 5 Year Change | -84.67% |
| Change since IPO | -75.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4QK | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.6% | -4.6% | 1.8% |
| 1Y | -25.9% | -8.0% | 2.2% |
Return vs Industry: 4QK underperformed the German Life Sciences industry which returned -14.9% over the past year.
Return vs Market: 4QK underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 4QK volatility | |
|---|---|
| 4QK Average Weekly Movement | 16.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4QK's share price has been volatile over the past 3 months.
Volatility Over Time: 4QK's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 174 | Stephen Dilly | www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
Codexis, Inc. Fundamentals Summary
| 4QK fundamental statistics | |
|---|---|
| Market cap | €190.47m |
| Earnings (TTM) | -€71.22m |
| Revenue (TTM) | €65.53m |
2.9x
P/S Ratio-2.7x
P/E RatioIs 4QK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4QK income statement (TTM) | |
|---|---|
| Revenue | US$70.14m |
| Cost of Revenue | US$71.69m |
| Gross Profit | -US$1.55m |
| Other Expenses | US$74.69m |
| Earnings | -US$76.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -2.21% |
| Net Profit Margin | -108.69% |
| Debt/Equity Ratio | 0% |
How did 4QK perform over the long term?
See historical performance and comparison